Atrial Fibrillation and Stroke. A Review on the Use of Vitamin K Antagonists and Novel Oral Anticoagulants

Atrial fibrillation (AF) is the most common arrhythmia, ranging from 0.1% in patients <55 years to >9% in octogenarian patients. One important issue is represented by the 5-fold increased ischemic stroke risk in AF patients. Hence, the role of anticoagulation is central. Until a few years ago,...

Descripción completa

Detalles Bibliográficos
Autores principales: Caturano, Alfredo, Galiero, Raffaele, Pafundi, Pia Clara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6843417/
https://www.ncbi.nlm.nih.gov/pubmed/31547188
http://dx.doi.org/10.3390/medicina55100617
_version_ 1783468210517966848
author Caturano, Alfredo
Galiero, Raffaele
Pafundi, Pia Clara
author_facet Caturano, Alfredo
Galiero, Raffaele
Pafundi, Pia Clara
author_sort Caturano, Alfredo
collection PubMed
description Atrial fibrillation (AF) is the most common arrhythmia, ranging from 0.1% in patients <55 years to >9% in octogenarian patients. One important issue is represented by the 5-fold increased ischemic stroke risk in AF patients. Hence, the role of anticoagulation is central. Until a few years ago, vitamin K antagonists (VKAs) and low molecular weight heparin represented the only option to prevent thromboembolisms, though with risks. Novel oral anticoagulants (NOACs) have radically changed the management of AF patients, improving both life expectancy and life quality. This review aims to summarize the most recent literature on the use of VKAs and NOACs in AF, in light of the new findings.
format Online
Article
Text
id pubmed-6843417
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-68434172019-11-25 Atrial Fibrillation and Stroke. A Review on the Use of Vitamin K Antagonists and Novel Oral Anticoagulants Caturano, Alfredo Galiero, Raffaele Pafundi, Pia Clara Medicina (Kaunas) Review Atrial fibrillation (AF) is the most common arrhythmia, ranging from 0.1% in patients <55 years to >9% in octogenarian patients. One important issue is represented by the 5-fold increased ischemic stroke risk in AF patients. Hence, the role of anticoagulation is central. Until a few years ago, vitamin K antagonists (VKAs) and low molecular weight heparin represented the only option to prevent thromboembolisms, though with risks. Novel oral anticoagulants (NOACs) have radically changed the management of AF patients, improving both life expectancy and life quality. This review aims to summarize the most recent literature on the use of VKAs and NOACs in AF, in light of the new findings. MDPI 2019-09-20 /pmc/articles/PMC6843417/ /pubmed/31547188 http://dx.doi.org/10.3390/medicina55100617 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Caturano, Alfredo
Galiero, Raffaele
Pafundi, Pia Clara
Atrial Fibrillation and Stroke. A Review on the Use of Vitamin K Antagonists and Novel Oral Anticoagulants
title Atrial Fibrillation and Stroke. A Review on the Use of Vitamin K Antagonists and Novel Oral Anticoagulants
title_full Atrial Fibrillation and Stroke. A Review on the Use of Vitamin K Antagonists and Novel Oral Anticoagulants
title_fullStr Atrial Fibrillation and Stroke. A Review on the Use of Vitamin K Antagonists and Novel Oral Anticoagulants
title_full_unstemmed Atrial Fibrillation and Stroke. A Review on the Use of Vitamin K Antagonists and Novel Oral Anticoagulants
title_short Atrial Fibrillation and Stroke. A Review on the Use of Vitamin K Antagonists and Novel Oral Anticoagulants
title_sort atrial fibrillation and stroke. a review on the use of vitamin k antagonists and novel oral anticoagulants
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6843417/
https://www.ncbi.nlm.nih.gov/pubmed/31547188
http://dx.doi.org/10.3390/medicina55100617
work_keys_str_mv AT caturanoalfredo atrialfibrillationandstrokeareviewontheuseofvitaminkantagonistsandnoveloralanticoagulants
AT galieroraffaele atrialfibrillationandstrokeareviewontheuseofvitaminkantagonistsandnoveloralanticoagulants
AT pafundipiaclara atrialfibrillationandstrokeareviewontheuseofvitaminkantagonistsandnoveloralanticoagulants

Ejemplares similares